ZIBO, China, Aug. 29, 2026 /PRNewswire/ — INTCO Medical (“the Company”, 300677.SZ), a leading global manufacturer of disposable gloves, reported revenue of RMB 6.91 billion (approx. US$1.03 billion) for the six months ended June 30, 2026, up 40.61% from a year earlier. Net profit attributable to shareholders rose 17.86% to RMB 837.3 million (approx. US$124.6 million). Adjusted net profit attributable to shareholders, excluding nonrecurring gains and losses, climbed 165.00% to RMB 1.06 billion (approx. US$157.7 million).

By the end of the reporting period, INTCO Medical’s annualized production capacity for disposable gloves had reached 107 billion pieces. The total comprised 74 billion disposable nitrile gloves and 33 billion disposable vinyl gloves. This scale reinforces the Company’s position as the world’s largest producer of disposable gloves.

INTCO Medical’s integrated value chain extends from nitrile latex and the research, development and manufacturing of core production equipment to glove production and global sales. Through nitrile latex manufacturers in which it holds controlling or equity interests, the Company strengthens raw material supply security, helping mitigate the impact of international crude oil price fluctuations on key raw material costs while enhancing supply stability and cost efficiency. Its coordinated domestic and international production capacity enables the Company to allocate manufacturing resources according to market demand, respond efficiently to customer needs and support reliable delivery across global markets. Together, these capabilities strengthen operational resilience.

During the reporting period, R&D expenses rose 20.62% to RMB 245.9 million (approx. US$36.6 million). The Company continued to develop high-performance products, including Syntex™ Synthetic Latex Gloves, a proprietary glove that does not contain natural latex proteins and offers high elasticity and puncture resistance, and Synmax Pro Exam Gloves, an enhanced vinyl glove for food service and industrial applications. The Company has also introduced safety work gloves, household gloves and other products to meet diverse application needs.

Smart manufacturing boosts efficiency and quality. INTCO Medical’s latest nitrile glove production line spans more than 1.6 kilometers and incorporates about 500 control points. Its precision distributed control system automatically manages temperature and liquid levels based on production conditions, helping reduce labor and energy consumption while maintaining stable output. The Company’s glove product yield remained above 99% during the reporting period.

INTCO Medical will continue optimizing global capacity and advancing protective product innovation to support growth.

SINGAPORE, Aug. 29, 2026 /PRNewswire/ — Noah Holdings Limited (the “Company” or “Noah”) (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors, today announced changes to its board of directors (the “Board”) and the composition of its Board committees.

Noah has appointed Ms. Tianjing Zhang as an independent director (a non-executive director for purposes of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Hong Kong Listing Rules”), effective August 29, 2026. Ms. Cynthia Jinhong Meng will retire as an independent director upon the expiration of the independent director agreement entered into between her and the Company at the end of August 28, 2026, after three years of service. Ms. Meng’s departure did not result from any disagreement with the Company and the Board expresses its sincere gratitude for her invaluable contribution during her tenure.

Mr. David Zhang has served as our independent director since June 2024 under applicable U.S. regulations, and, for purposes of the Hong Kong Listing Rules, a non-executive director. The Corporate Governance and Nominating Committee conducted a comprehensive assessment of the independence of Mr. David Zhang under Rule 3.13 of the Hong Kong Listing Rules, including the circumstances contemplated under Rules 3.13(3) and 3.13(7). In particular, they considered, among other matters, that the two-year cooling-off period contemplated under Rule 3.13(3) had expired before Mr. Zhang provided his confirmation of independence and that more than two and a half years had elapsed since he retired from Kirkland & Ellis in January 2024. They also considered that Mr. Zhang has not held any executive or management position within the Company or its subsidiaries and that his involvement has been limited to Board-level and Audit Committee oversight. After considering all relevant facts and circumstances and Mr. Zhang’s confirmation of independence, the Board and the Corporate Governance and Nominating Committee are satisfied that he is independent for purposes of Rule 3.13 of the Hong Kong Listing Rules and he has been re-designated as an independent Director under the Hong Kong Listing Rules, with effect from August 29, 2026. The Board is confident that Mr. Zhang’s expertise in cross-border securities offerings, U.S. and Hong Kong capital markets and dual-listed company governance will strengthen the Board’s independent oversight and committee functions.

In connection with Ms. Meng’s retirement and the appointment and/or re-designation described above, the Board has resolved to change the composition of its committees with effect from August 29, 2026. The Audit Committee shall comprise Ms. Xiangrong Li as Chairperson, Mr. David Zhang and Ms. Tianjing Zhang as members. The Compensation Committee shall comprise Ms. May Yihong Wu as Chairperson, Mr. Boquan He and Ms. Xiangrong Li as members. The Corporate Governance and Nominating Committee shall comprise Ms. Jingbo Wang as Chairperson, Ms. May Yihong Wu and Mr. David Zhang as members.

Ms. Tianjing Zhang has nearly two decades of experience in cross-border disputes, regulatory investigations, crisis management, compliance and international legal risk management. She has served as head of international business of HOZU Capital since May 2025, where she focuses on assessing and underwriting international arbitration and litigation matters and makes investment recommendations. From January 2012 to April 2025, Ms. Zhang practiced at Kirkland & Ellis International LLP and served as managing partner and chief representative of its Shanghai office before her resignation. During her tenure, she led the firm’s China cross-border dispute resolution and government, regulatory and investigations practice, representing global clients in complex multi-jurisdictional litigation and government-led and internal investigations. Before joining Kirkland & Ellis International LLP, she practiced at Holland & Knight LLP in San Francisco from April 2008 to December 2011, and appeared before U.S. federal and state courts.

Ms. Zhang holds a Juris Doctor degree from The University of Texas School of Law, a Master of Arts degree in political science (international relations) from Georgetown University and a Bachelor of Laws degree in international law from China Foreign Affairs University. She is admitted to practice law in the State of California, U.S. Ms. Zhang was named “Leading Lawyer of the Year” at The Legal 500 China Awards 2023 and has also been recognized by The Legal 500 Asia Pacific, Chambers and Partners and Benchmark Litigation Asia-Pacific.

Ms. Jingbo Wang, co-founder and chairwoman of Noah, commented, “I would like to express my sincere gratitude to Ms. Meng for her contributions to Noah where her dedication and guidance was instrumental in strengthening our governance framework. I wish her all the best in her future endeavors. I’d also like to extend a warm welcome to Ms. Tianjing Zhang where I am confident her extensive legal and regulatory experience will prove invaluable in shaping our future strategic direction. I am also pleased that Mr. David Zhang has been re-designated as an independent director under the Hong Kong Listing Rules, reflecting the Board’s confidence in his independence and expertise. These changes strengthen the Board’s legal, regulatory, capital markets and corporate governance expertise, broaden its diversity of perspectives and reinforce our commitment to the highest standards of corporate governance.”

ABOUT NOAH HOLDINGS LIMITED

Noah Holdings Limited (NYSE: NOAH and HKEX: 6686) is a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors. Noah’s American depositary shares, or ADSs, are listed on the New York Stock Exchange under the symbol “NOAH,” and its shares are listed on the Main Board of the Hong Kong Stock Exchange under the stock code “6686.” One ADS represents five ordinary shares, par value $0.00005 per share. 

In the first half of 2026, Noah distributed RMB40.4 billion (US$6.0 billion) of investment products. Through Gopher Asset Management and Olive Asset Management, Noah had assets under management of RMB140.9 billion (US$20.8 billion) as of June 30, 2026.

Founded in 2005, the firm pioneered a business model combining wealth management and asset management and has continued to build its international platform over the years. As of June 30, 2026, Noah had 469,987 registered clients. The Company reports its operations under six business segments — Mainland China public securities (Noah Upright), Mainland China asset management (Gopher Asset Management), Mainland China insurance (Glory), International wealth management (ARK Wealth Management), International asset management (Olive Asset Management), and International insurance and comprehensive services (Glory Family Heritage) — plus headquarters. As of June 30, 2026, Noah had established branches and service capabilities across mainland China, Hong Kong, Singapore, Japan, and key U.S. markets, including New York, Los Angeles, and Silicon Valley, reflecting its international operating footprint. 

For more information, please visit Noah’s investor relations website at ir.noahgroup.com.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Noah may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in announcements, circulars or other publications made on the website of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Noah’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. These statements include, but are not limited to, estimates regarding the sufficiency of Noah’s cash and cash equivalents and liquidity risk. A number of factors could cause Noah’s actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: its goals and strategies; its future business development, financial condition and results of operations; the expected growth of the wealth management and asset management market in China and internationally; its expectations regarding demand for and market acceptance of the products it distributes; investment risks associated with investment products distributed to Noah’s investors, including the risk of default by counterparties or loss of value due to market or business conditions or misconduct by counterparties; its expectations regarding keeping and strengthening its relationships with key clients; relevant government policies and regulations relating to its industries; its ability to attract and retain qualified employees; its ability to stay abreast of market trends and technological advances; its plans to invest in research and development to enhance its product choices and service offerings; competition in its industries in China and internationally; general economic and business conditions in China; and its ability to effectively protect its intellectual property rights and not to infringe on the intellectual property rights of others. Further information regarding these and other risks is included in Noah’s filings with the U.S. Securities and Exchange Commission and the Hong Kong Stock Exchange. All information provided in this press release and in the attachments is as of the date of this press release, and Noah does not undertake any obligation to update any such information, including forward-looking statements, as a result of new information, future events or otherwise, except as required under the applicable law.

HONG KONG, Aug. 29, 2026 /PRNewswire/ — LifeTech Scientific Corporation (“LifeTech” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2026 (the “Reporting Period”).

• The Group achieved revenue of approximately RMB600.8 million during the Reporting Period.

• Gross profit was approximately RMB465.9 million, while gross profit margin increased 3.9 percentage points to approximately 77.5% for the six months ended 30 June 2026. Excluding certain non-recurring items^[1], net profit attributable to owners of the Company was approximately RMB114.8 million, during the Reporting Period.

• As at 30 June 2026, the Group’s cash and cash equivalents amounted to approximately RMB953.8 million, representing an increase of approximately 32.6% compared with 31 December 2025.

Tackling Domestic-market Challenges, Fueling Overseas Revenue Growth

In the first half of 2026, the Group maintained a sharp focus on addressing unmet clinical needs worldwide, leveraging its synergies in branding, intellectual property, distribution networks, clinical registration, and global operations. With an increasingly diversified and refined innovative product portfolio, complemented by professional academic services, the Group steadily consolidated its foundation for long-term growth.

China’s mainland remained the largest market of the Group, where the revenue generated accounted for approximately 69.6% of the total revenue during the Reporting Period.

Meanwhile, our overseas business maintained its upward momentum. The overseas sales of the Group grew by approximately 4.1% (approximately 8.2% in USD) year-on-year. Asia (excluding China’s mainland) and Europe were the two largest overseas markets of the Group, which accounted for approximately 10.3% and 12.6%, respectively, of the total revenue of the Group for the six months ended 30 June 2026.

Long-term Focus, Deep Roots in Core Markets

Structural Heart Diseases Business
The Group has established a diversified product portfolio in the Structural Heart Diseases (SHD) business, mainly including LAA occluders and three generations of congenital heart diseases occluders, aiming to address various market demands through differentiated product strategies.

During the Reporting Period, the sales contributed by the SHD business were approximately RMB200.1 million.

Continuous technological innovation and product upgrades will further enrich the SHD product portfolio of the Group and enhance its global sales layout.

Peripheral Vascular Diseases Business
The Group is committed to providing patients worldwide with technology-leading systematic and comprehensive interventional medical devices solutions to treat Peripheral Vascular Diseases (PVD).

The products offered by the Group in the PVD business mainly include vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts, iliac artery bifurcation stent grafts, aortic stent graft systems, aortic arch stent graft systems and thoracoabdominal aortic stent graft systems.

During the Reporting Period, the sales contributed by the PVD business were approximately RMB400.7 million, representing a year-on-year growth of approximately 2.3%, of which the revenue generated from the sales of stent grafts and vena cava filters increased by approximately 2.9% and 2.6% year-on-year, respectively.

Cardiac Pacing and Electrophysiology Business
The Group recorded no sales contribution from its cardiac pacing and electrophysiology business during the Reporting Period.

R&D and Commercialization Progress

The Group adheres to independent innovation, aiming to provide medical devices that deliver outstanding clinical value for physicians and patients worldwide, while continuously enhancing its long-term competitiveness.

During the Reporting Period, the Group invested approximately RMB167.1 million in research and development (including capitalized expenditure). This investment will further enhance our innovation capabilities, accelerate the development and commercialization of our products, as well as to sustain our industry‑leading position.

During the six months ended 30 June 2026, we have achieved the following milestones in the R&D field:

• Iliac Bifurcation Device (consisting of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System) and Peripheral High Pressure Balloon Dilatation Catheter have obtained the National Medical Products Administration (“NMPA”) certification;

• G-iliac™ Iliac Bifurcation Stent Graft System and SilverFlow™ Internal Iliac Stent Graft System have obtained the CE MDR (Medical Device Regulation) certification;

• Cera™ PFO Occluder, CeraFlex™ PFO Occluder, FuStar™ Steerable Introducer, SeQure™ Snare System and SteerEase™ Introducer have obtained the CE MDR certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;

• Cera™ PFO Occluder, Yuranos™ Pro Abdominal Aortic Stent Graft System and Constraining Structure PTA Balloon Catheter, etc. are pending registration approval in China;

• Aortic Stent Graft System (consisting of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, Thoracoabdominal Artery Stent Graft System (consisting of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System, G-Branch™ AE Main Body Extension Stent Graft System, G-Branch™ AAA Bifurcated Stent Graft System and G-Branch™ IE Iliac Extension Stent Graft System) and Aortic Arch Stent Graft System (consisting of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System) are pending registration approval of CE certification;

• X-Clip™ Mitral Valve Clip System and Nitinol Patent Ductus Arteriosus Occluder are currently at the stage of pre-registration clinical enrollment in China;

• CS™ Concave Supra-arch Branched Stent-Graft System and SureCham™ Aortic Arch Single Branch Stent Graft System (consisting of the Aortic Arch Stent Graft System and Aortic Branch Stent Graft System) have completed pre-marketing clinical enrollment and are currently under clinical follow-up in China;

• IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe, and its CE registration application has been submitted;

• IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the five-year follow-up of the phase I clinical study and the three-year follow-up of the phase II and III clinical study, further confirming its safety and efficacy. Additionally, its CE and NMPA registration application have been submitted; and

• CS™ Concave Supra-arch Branched Stent-Graft System has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices, which is the 17th product of the Company to have obtained admission to the Procedure.

Intellectual Property Rights

Intellectual property is an important intangible asset of the Group and also an internal driving force to improve our core competitiveness in the medical device market. As at 30 June 2026, the Group has filed a total of 2,608 valid patent applications, of which 1,370 patents were registered and valid.

The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:
In the first half of 2026, the global medical device industry continued to undergo profound transformation. Despite external volatility posing certain challenges to the Group’s short-term operations, we remained steadfast in our strategic focus, deepened our presence in core markets, and drove differentiated competition through technological innovation. Our product sales mix continued to improve, and all operational activities proceeded in an orderly manner.

Guided by our two core development strategies of “innovation” and “internationalization”, we will accelerate breakthroughs in key technologies through forward-looking initiatives, further refine our systematic disease solutions, and leverage a more complete, diverse, and efficient portfolio of innovative products to steadily expand our global footprint and consolidate our industry‑leading position, thereby maintaining robust resilience amid the ongoing transformation and evolution of the global medical device sector.

The global healthcare industry holds vast prospects. Looking ahead, we will continue to focus on technological advancement and operational efficiency optimization. Leveraging our strong R&D capabilities, robust industrialization capacity, and outstanding global operation and management expertise, we aim to seize opportunities and address challenges to pursue sustainable and high‑quality growth, creating long‑term value for patients, healthcare institutions, shareholders, and all other stakeholders with unwavering dedication.

About LifeTech Scientific Corporation

Established in 1999 in Shenzhen, China, LifeTech Scientific Corporation (Stock Code: 1302.HK) specializes in the R&D, manufacturing, and sales of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurovascular conditions. It also possesses the world’s first innovative iron-based bioabsorbable material technology platform. Guided by the core strategy of “innovation” and “internationalization”, LifeTech maintains a leading market position for its key products in the home country and has established 7 subsidiaries overseas, extending its sales network to nearly 120 countries and regions worldwide.

• ClubMed Lifestyle Group’s revenue reached EUR1.95 billion in 2025.
• Adjusted EBITDA reached EUR 390 million in 2025, with the adjusted EBITDA margin rising to 20.2% in 2025.
• ClubMed Lifestyle Group expects to operate approximately 85 resorts worldwide by 2030.
• Upon completion of the proposed listing, proceeds from the proposed listing will be used primarily to expand its global resort network, upgrade its vacation offerings, and strengthen its digital and AI capabilities.

HONG KONG, Aug. 29, 2026 /PRNewswire/ — According to an announcement published by Fosun International Limited, ClubMed Lifestyle Group, a subsidiary of Fosun International Limited, has submitted a listing application to the Hong Kong Stock Exchange for its proposed separate listing on the Main Board. The joint sponsors are BNP Paribas, HSBC and J.P. Morgan, in alphabetical order.

According to the listing application materials, ClubMed Lifestyle Group operates premium all-inclusive resorts with Club Med as its core brand. It also expands its vacation offerings including Integrated Vacation Destinations and Cultural-Tourism Complexes through an asset-light model, as it continues to build diversified vacation lifestyles.

Global Leader in High-Quality Vacation Lifestyles Pursues Hong Kong Listing

Club Med is the core brand of ClubMed Lifestyle Group. According to the listing application materials, Club Med was the world’s largest all-inclusive resort brand by revenue in 2025, ranking first in both Europe, the Middle East and Africa (EMEA) and Asia-Pacific. By number of resorts in 2025, Club Med is also the world’s largest mountain and ski resort brand.

To date, Club Med has established a global sales network spanning six continents and more than 40 countries and regions. It operates 69 premium resorts worldwide across a diverse range of destinations, including mountain and ski locations and sun-and-beach destinations. It is also the only resort brand with a presence in all four of the world’s major ski destinations.

According to the listing application materials, ClubMed Lifestyle Group’s revenue increased from EUR1.86 billion in 2023 to EUR1.95 billion in 2025, while gross profit rose from EUR 540 million to EUR 590 million. Adjusted EBITDA reached EUR 390 million in 2025, with the adjusted EBITDA margin rising to 20.2% in 2025. Club Med completed the premiumization of its entire portfolio in 2024, and its premium product portfolio has continued to deliver pricing benefits.

In 2026, Club Med was named to TIME’s list of the 100 Most Influential Companies in the world, becoming the only hotel and resort brand included that year.

In addition, leveraging Club Med’s brand influence and global operating capabilities, ClubMed Lifestyle Group expands its vacation offerings through an asset-light model, as it continues to build diversified vacation lifestyles. In terms of market size, the global vacation lifestyle market is expected to grow from USD 2.5 trillion in 2025 to USD 3.5 trillion in 2030.

Proceeds from the proposed listing will be used for the expansion and upgrade of its global resort business

The global vacation lifestyle industry is not only continuing to grow but is also evolving towards more integrated vacation offerings. In particular, consumer preferences are shifting from sightseeing to leisure travel, while spending power and expenditure on experiential consumption continue to increase. With the emergence of new technologies such as AI and digitalisation, the range of integrated vacation products and services available to consumers is also becoming increasingly diversified.

As a pioneer and leader of both “Lifestyle Vacation” and “Everyday Vacation”, ClubMed Lifestyle Group possesses distinctive advantages and core competitiveness in developing high-quality leisure vacation lifestyles.

ClubMed Lifestyle Group has a 76-year brand heritage, a premium all-inclusive resort model and a distinctive G.O. (Gentils Organisateurs, or “Gracious Organisers”) culture. These qualities enable the Group to provide guests with immersive vacation experiences characterised by active participation and emotional connection.

According to the listing application materials, ClubMed Lifestyle Group plans to accelerate its expansion into premium tourism destinations around the world, including the Alps, the southern Mediterranean, North Africa, Northeast Asia, Southeast Asia, North America and the Caribbean, and South America while exploring emerging markets such as the Middle East. ClubMed Lifestyle Group expects to operate approximately 85 resorts worldwide by 2030.

Upon completion of the proposed listing, the proceeds from ClubMed Lifestyle Group’s proposed listing will be used primarily to expand its global resort network, upgrade its vacation offerings, and strengthen its digital and AI capabilities. The remaining proceeds are expected to be used to optimise its capital structure and support its day‑to‑day business operations.

Xu Xiaoliang, Chairman of ClubMed Lifestyle Group said: “The submission of the listing application in Hong Kong marks an important milestone for Fosun’s tourism business as it moves towards value creation. Going forward, we will take Club Med as our core brand to accelerate the development of the global high-quality resorts. We aim to make happy holidays a lifestyle that transcends borders, and to realise our vision that ‘Better Vacation, Better Life’.”

Disclaimer

This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or in any other jurisdiction. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration under the U.S. Securities Act or an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. No public offering of securities will be made in the United States.